Talk Therapy After Stroke
Overview
Strokes are the first cause of acquired physical disability among adults. Some studies proved that depression is often an unrecognized complication from stroke, associated with a vital prognosis, functional and cognitive pejorative diagnosis. It led us to pose the hypothesis of the existence of a particular psychological state after stroke particularly favorable to a psychotherapeutic alliance. So, this longitudinal monocentric study aims to estimate the feasibility of a talk therapy and its impact on the anxio-depressive symptomatology after stroke.
Full Title of Study: “Talk Therapy After Stroke. PS-POST AVC”
Study Type
- Study Type: Interventional
- Study Design
- Allocation: N/A
- Intervention Model: Single Group Assignment
- Primary Purpose: Treatment
- Masking: None (Open Label)
- Study Primary Completion Date: May 2012
Interventions
- Behavioral: talk therapy
- Psychotherapy
Arms, Groups and Cohorts
- Experimental: Talk therapy
- A cohort of 25 patients
Clinical Trial Outcome Measures
Primary Measures
- acceptability
- Time Frame: at 6 months
- Participation rate in the study
Secondary Measures
- Rates of anxiety and depression
- Time Frame: at 3 and 6 months
- Montgomery and Asberg Depression Rating Scale(depressive patients) and wide COVI (anxious patients)
- Evaluation of quality of life
- Time Frame: at 3 and 6 months
- MM20-QOL scale
- Evaluation of functional recovery
- Time Frame: at 3 and 6 months
- Barthel index and Rankin score NIHSS score
- Assessment of apathy
- Time Frame: at 3 and 6 months
- apathy index
- Categorization of patients
- Time Frame: 6 months
- according to their pattern of coping with specific scales and RWCQ (Revised Ways of Coping Questionnaire – stroke modified version) QSSP (Questionnaire de soutien social perçu)
Participating in This Clinical Trial
Inclusion Criteria
- ischemic or aemoragic stroke minor 1 week, confirmed by cerebral imaging Exclusion Criteria:
- severe aphasia (NIHSS criteria 9: sup or egal: 2) – Chronic psychiatric preexistant desease.
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: 85 Years
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Centre Hospitalier Universitaire de Nice
- Provider of Information About this Clinical Study
- Sponsor
- Overall Official(s)
- Hélène MAHAGNE, PH, Study Director, Centre Hospitalier Universitaire de Nice
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.